How to appeal a CareFirst BCBS plaque psoriasis + psoriatic arthritis denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for plaque psoriasis + psoriatic arthritis

Cited policy: BCBS Humira / Adalimumab Biosimilar PsA + Plaque PA

Plaque: BSA >=3% with special-site or BSA >=10% / PASI >=12 / DLQI >=10. PsA: ACR criteria + active disease (TJC/SJC >=3 or axial/enthesitis/dactylitis) + MTX failure or contraindication. Mandatory adalimumab biosimilar substitution (Cyltezo interchangeable preferred) unless dispense-as-written justification.

How CareFirst BCBS denies plaque psoriasis + psoriatic arthritis — and how to counter it

Where CareFirst BCBS pushes back: 1) MTX trial inadequate for PsA; 2) Must use Cyltezo/biosimilar instead of branded Humira; 3) BSA <3%; 4) Latent TB / HBV not screened.

Counter-arguments that hold up: ACR/NPF 2018 PsA (Singh) + GRAPPA 2021 + EULAR 2023 PsA — severe peripheral arthritis / axial / enthesitis / dactylitis / erosive disease can go directly to TNFi without MTX trial. SEAM-PsA: MTX inferior to etanercept wk 24. REVEAL (Menter JAAD 2008) PASI 75 71% wk 16. CHAMPION — Humira > MTX. For Cimzia: pregnancy-friendly (no Fc receptor → no transplacental transfer; Mariette ARD 2018). Biosimilar substitution acceptable but does NOT bypass primary-failure class-switch — failing branded Humira predicts failing biosimilar (same molecule).

What CareFirst BCBS typically denies for plaque psoriasis + psoriatic arthritis

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For plaque psoriasis + psoriatic arthritis, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the plaque psoriasis + psoriatic arthritis treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Cimzia
• Simponi
• Cosentyx

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.